Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
复制标题
DOI：
10.1093/schbul/sby058
复制
发表时间：
2018-11-01
影响因子：
6.6
通讯作者：
Whiteford, Harvey A.
中科院分区：
文献类型：
--
作者：
Charlson, Fiona J.;Ferrari, Alize J.;Whiteford, Harvey A.
简介：全球疾病负担 (GBD) 研究得出了精神分裂症详细且可比较的流行病学和疾病负担估计。我们报告了 GBD 2016 年对所有国家精神分裂症患病率和疾病负担的估计，并按年龄、性别、年份进行分类。方法：我们进行了系统回顾，以确定报告与精神分裂症相关的患病率、发病率、缓解和/或超额死亡率的研究。报告的符合我们纳入标准的估计值被输入 GBD 2016 中使用的贝叶斯元回归工具中，以得出 20 个年龄组、7 个超级区域、21 个地区以及 195 个国家和地区的患病率。通过将年龄、性别、年份和地点特定患病率乘以代表这些状态期间经历的残疾的 2 个残疾权重，得出精神分裂症急性和残留状态的疾病负担估计值。结果：系统审查总共发现了 129 个单独的数据源。 2016 年全球精神分裂症年龄标准化点患病率估计为 0.28%（95% 不确定区间 [UI]：0.24-0.31）。未观察到患病率存在性别差异。不同国家或地区的年龄标准化点患病率差异不大。在全球范围内，患病病例从 1990 年的 13.1（95% UI：11.6-14.8）万例上升到 2016 年的 20.9（95% UI：18.5-23.4）万例。精神分裂症对全球残疾疾病负担的影响为 13.4（95% UI：9.9-16.7）万年。结论：虽然精神分裂症是一种低患病率的疾病，但疾病负担却很重。我们的模型表明，人口的显着增长和老龄化导致了精神分裂症造成的巨大且不断增加的疾病负担，特别是对于中等收入国家。
Introduction: The global burden of disease (GBD) studies have derived detailed and comparable epidemiological and burden of disease estimates for schizophrenia. We report GBD 2016 estimates of schizophrenia prevalence and burden of disease with disaggregation by age, sex, year, and for all countries. Method: We conducted a systematic review to identify studies reporting the prevalence, incidence, remission, and/or excess mortality associated with schizophrenia. Reported estimates which met our inclusion criteria were entered into a Bayesian meta-regression tool used in GBD 2016 to derive prevalence for 20 age groups, 7 super-regions, 21 regions, and 195 countries and territories. Burden of disease estimates were derived for acute and residual states of schizophrenia by multiplying the age-, sex-, year-, and location-specific prevalence by 2 disability weights representative of the disability experienced during these states. Findings: The systematic review found a total of 129 individual data sources. The global age- standardized point prevalence of schizophrenia in 2016 was estimated to be 0.28% (95% uncertainty interval [UI]: 0.24-0.31). No sex differences were observed in prevalence. Age-standardized point prevalence rates did not vary widely across countries or regions. Globally, prevalent cases rose from 13.1 (95% UI: 11.6-14.8) million in 1990 to 20.9 (95% UI: 18.5-23.4) million cases in 2016. Schizophrenia contributes 13.4 (95% UI: 9.9-16.7) million years of life lived with disability to burden of disease globally. Conclusion: Although schizophrenia is a low prevalence disorder, the burden of disease is substantial. Our modeling suggests that significant population growth and aging has led to a large and increasing disease burden attributable to schizophrenia, particularly for middle income countries.